awmsg logo



anakinra (Kineret®)


Reference No. 3734

Publication date:
25/07/2018


Appraisal information

anakinra (Kineret®) 100 mg/0.67 ml solution for injection


Company: Swedish Orphan Biovitrum Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 23/07/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, anakinra (Kineret®) cannot be endorsed for use within NHS Wales in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease, with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs or glucocorticoids.
Statement of Advice (SOA)
Download